Relmada Therapeutics to Present at LD Micro Invitational Conference in Los Angeles

Description

Company Presentation Scheduled for Wednesday June 5, 2019 at 11:40 a.m. Pacific Time.

NEW YORK, June 3, 2019 /PRNewswire/ — Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced today that it will present an overview of the company's business operations and progress in clinical research and product development at the LD Micro Invitational Conference on Wednesday, June 5, 2019 at the Luxe Sunset Bel Air Hotel in Los Angeles, CA.

Relmada Therapeutics Corporate Logo

The presentation by Sergio Traversa, CEO of Relmada Therapeutics, is scheduled to begin at 11:40 a.m. PT (2:40 p.m. Eastern Time). Management will also be available for one-on-one meetings with investors throughout the day.

A live webcast of the presentation will be available through the Company's website at www.relmada.com/ir-calendar. Please register at least 10 minutes prior to the start of the presentation to ensure timely access. The webcast and presentation will also be archived on the website for 90 days after the conference.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada's lead program, dextromethadone (REL-1017), is an N-methyl-D-aspartate (NMDA) receptor antagonist. NMDA receptor antagonists may have potential in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms. For more information, please visit Relmada's website at www.relmada.com.

Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. We may from time to time make written or oral statements in this letter, the proxy statements filed with the SEC communications to stockholders and press releases which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based

upon management's current expectations, estimates, assumptions and beliefs concerning future events and conditions and may discuss, among other things, anticipated future performance, expected product development, product potential, future business plans and costs. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to" and similar expressions. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all of the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be considered to be a complete list.

Investor Contact
Brian Ritchie
LifeSci Advisors
T. 212 915 2578
britchie@lifesciadvisors.com

Media contact:
Bill Berry
Berry & Company Public Relations
T. 212.253.8881
bberry@berrypr.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/relmada-therapeutics-to-present-at-ld-micro-invitational-conference-in-los-angeles-300860525.html

SOURCE Relmada Therapeutics, Inc.

Released June 3, 2019

Date Created
2019/06/03